519 related articles for article (PubMed ID: 36998426)
21. Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory.
Sartore-Bianchi A; Loupakis F; Argilés G; Prager GW
Ann Oncol; 2016 Aug; 27(8):1456-66. PubMed ID: 27154421
[TBL] [Abstract][Full Text] [Related]
22. Current and advancing treatments for metastatic colorectal cancer.
Sanz-Garcia E; Grasselli J; Argiles G; Elez ME; Tabernero J
Expert Opin Biol Ther; 2016; 16(1):93-110. PubMed ID: 26549053
[TBL] [Abstract][Full Text] [Related]
23. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.
Lin PS; Semrad TJ
Methods Mol Biol; 2018; 1765():281-297. PubMed ID: 29589315
[TBL] [Abstract][Full Text] [Related]
24. Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer.
Jeong WJ; Cha PH; Choi KY
World J Gastroenterol; 2014 Aug; 20(29):9862-71. PubMed ID: 25110417
[TBL] [Abstract][Full Text] [Related]
25. The genomic landscape of response to EGFR blockade in colorectal cancer.
Bertotti A; Papp E; Jones S; Adleff V; Anagnostou V; Lupo B; Sausen M; Phallen J; Hruban CA; Tokheim C; Niknafs N; Nesselbush M; Lytle K; Sassi F; Cottino F; Migliardi G; Zanella ER; Ribero D; Russolillo N; Mellano A; Muratore A; Paraluppi G; Salizzoni M; Marsoni S; Kragh M; Lantto J; Cassingena A; Li QK; Karchin R; Scharpf R; Sartore-Bianchi A; Siena S; Diaz LA; Trusolino L; Velculescu VE
Nature; 2015 Oct; 526(7572):263-7. PubMed ID: 26416732
[TBL] [Abstract][Full Text] [Related]
26. Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer.
Baek SK; Lee KT; Bae SB; Lee SC
Korean J Intern Med; 2019 Nov; 34(6):1188-1196. PubMed ID: 31346151
[TBL] [Abstract][Full Text] [Related]
27. Targeted therapy in advanced colorectal cancer: more data, more questions.
Ochenduszko SL; Krzemieniecki K
Anticancer Drugs; 2010 Sep; 21(8):737-48. PubMed ID: 20631611
[TBL] [Abstract][Full Text] [Related]
28. Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications.
Hanna DL; Lenz HJ
Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1091-108. PubMed ID: 27031164
[TBL] [Abstract][Full Text] [Related]
29. Personalizing medicine for metastatic colorectal cancer: current developments.
Marques AM; Turner A; de Mello RA
World J Gastroenterol; 2014 Aug; 20(30):10425-31. PubMed ID: 25132758
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer.
Saridaki Z; Georgoulias V; Souglakos J
World J Gastroenterol; 2010 Mar; 16(10):1177-87. PubMed ID: 20222160
[TBL] [Abstract][Full Text] [Related]
31. Epidermal growth factor receptor and metastatic colorectal cancer: insights into target therapies.
de Mello RA; Marques AM; Araújo A
World J Gastroenterol; 2013 Oct; 19(38):6315-8. PubMed ID: 24151349
[TBL] [Abstract][Full Text] [Related]
32. Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments.
Tang YL; Li DD; Duan JY; Sheng LM; Wang X
World J Gastroenterol; 2023 Feb; 29(6):926-948. PubMed ID: 36844139
[TBL] [Abstract][Full Text] [Related]
33. Targeted Therapy of Colorectal Cancer.
Seeber A; Gastl G
Oncol Res Treat; 2016; 39(12):796-802. PubMed ID: 27889786
[TBL] [Abstract][Full Text] [Related]
34. Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer.
Wang G; He Y; Sun Y; Wang W; Qian X; Yu X; Pan Y
Clin Transl Oncol; 2020 Jun; 22(6):813-822. PubMed ID: 31587152
[TBL] [Abstract][Full Text] [Related]
35. Rationally designed treatment for metastatic colorectal cancer: current drug development strategies.
Spiliopoulou P; Arkenau HT
World J Gastroenterol; 2014 Aug; 20(30):10288-95. PubMed ID: 25132745
[TBL] [Abstract][Full Text] [Related]
36. Addressing Resistance to Targeted Therapies in Metastatic Colorectal Cancer.
Jones J; Ciombor K; Wu C; Bekaii-Saab T; Strickler J
Oncology (Williston Park); 2021 Oct; 35(10):654-660. PubMed ID: 34677922
[TBL] [Abstract][Full Text] [Related]
37. Emerging VEGF-receptor inhibitors for colorectal cancer.
Martinelli E; Troiani T; Morgillo F; Orditura M; De Vita F; Belli G; Ciardiello F
Expert Opin Emerg Drugs; 2013 Mar; 18(1):25-37. PubMed ID: 23216053
[TBL] [Abstract][Full Text] [Related]
38. Novel agents in the treatment of metastatic colorectal cancer.
Leong S; Messersmith WA; Tan AC; Eckhardt SG
Cancer J; 2010; 16(3):273-82. PubMed ID: 20526106
[TBL] [Abstract][Full Text] [Related]
39. HER2 targeted therapy in colorectal cancer: New horizons.
Suwaidan AA; Lau DK; Chau I
Cancer Treat Rev; 2022 Apr; 105():102363. PubMed ID: 35228040
[TBL] [Abstract][Full Text] [Related]
40. Molecular Genetics and the Role of Molecularly Targeted Agents in Metastatic Colorectal Carcinoma.
Naeem A; Tun AM; Guevara E
J Gastrointest Cancer; 2020 Jun; 51(2):387-400. PubMed ID: 31273629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
